Shattuck Labs (STTK) Corporate presentation summary

Strategic focus and mission

• Dedicated to developing novel biologics for inflammatory and immune-mediated diseases, emphasizing scientific excellence and resource stewardship.

• Aims to create innovative therapeutics by challenging conventional approaches and focusing on patient impact.

Pipeline and lead program

• Lead asset SL-325 is a potentially first-in-class DR3 blocking antibody targeting the TL1A/DR3 axis for inflammatory bowel disease (IBD), with Phase 1 enrollment complete and data expected in Q2 2026.

• Pipeline includes SL-425 (extended half-life DR3 antibody) and bispecific antibodies targeting DR3 and other validated IBD targets.

• Blocking DR3 may offer more potent and durable inhibition of the TL1A/DR3 axis and lower immunogenicity compared to TL1A blockade.

Scientific rationale and differentiation

• DR3 is constitutively and more abundantly expressed in GI tissue and blood of IBD patients than TL1A, supporting its selection as a therapeutic target.

• Preclinical data show DR3 inhibition fully prevents CD-like ileitis in mouse models, outperforming TL1A inhibition.

• SL-325 demonstrates picomolar binding affinity to DR3, does not bind decoy receptor DcR3, and blocks both monomeric and trimeric TL1A.